All In Biotech

Drug Trial Radar · NCT07729462

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, RANDOMIZED, 2-ARM STUDY TO INVESTIGATE THE PREVENTION OF CHRONIC MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN PARTICIPANTS 18 YEARS OF AGE OR OLDER

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 26, 2026

Primary completion

Oct 21, 2028

Study completion Jan 19, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every other day. This study evaluates once daily rimegepant for the preventive treatment of chronic migraine. After a 28-day observation period without study intervention, eligible participants will be randomized in a 1:1 ratio to receive either rimegepant 75 mg orally disintegrating tablet (ODT) or matching placebo once daily for 12 weeks under double-blind conditions. Participants who remain eligible at the end of the double-blind treatment phase will enter a 12-week open-label treatment period, during which all participants will receive open-label rimegepant 75 mg once daily. During this period, participants may also take an additional rimegepant tablet for the acute treatment of breakthrough migraine attacks, up to 10 doses per month. A 28-day follow-up period completes the approximately 32-week study. The primary objective of the study is to determine whether once-daily rimegepant is more effective than placebo in reducing monthly migraine days relative to the observation period in adults with chronic migraine. Secondary objectives include evaluating differences between rimegepant and placebo in migraine responder rates, headache severity, acute migraine medication use, quality of life, work productivity, cognitive functioning, and safety and tolerability. Approximately 400 adults aged 18 years or older with a diagnosis of chronic migraine for at least 1 year will be enrolled at multiple study sites.

Conditions

  • Preventive Treatment of Migraine

Interventions

  • RimegepantDrug

    Rimegepant 75 mg orally disintegrating tablet (ODT) administered once daily during the 12-week double-blind treatment phase. Participants who enter the 12-week open-label extension phase will receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough headache attacks, up to 10 doses per month.

  • PlaceboDrug

    Matching placebo orally disintegrating tablet administered once daily during the 12-week double-blind treatment phase. Participants who enter the 12-week open-label extension phase will receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough headache attacks, up to 10 doses per month.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Observation Phase in Monthly Migraine Days (MMDs) Over the Entire Double-Blind Treatment PhaseTime frame: 12 Weeks

Locations

38 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Endpoints

    Scottsdale, Arizona · Recruiting

  • Hope Clinical Research

    Canoga Park, California · Recruiting

  • Neuro-Pain Research Center

    Fresno, California · Recruiting

  • Clinical Research Institute

    Los Angeles, California · Recruiting

  • Neurology Offices of South Florida PLLC

    Boca Raton, Florida · Recruiting

  • Brainstorm Research Inc.

    Miami, Florida · Recruiting

  • Conquest Research-Winter Park

    Winter Park, Florida · Recruiting

  • Conquest Research, LLC

    Atlanta, Georgia · Not yet recruiting

  • Josephson Wallack Munshower Neurology,PC

    Indianapolis, Indiana · Recruiting

  • Collective Medical Research

    Overland Park, Kansas · Recruiting

  • New England Regional Headache Center, Inc.

    Worcester, Massachusetts · Recruiting

  • Michigan Headache & Neurological Institute

    Ann Arbor, Michigan · Recruiting

  • StudyMetrix Research

    City of Saint Peters, Missouri · Recruiting

  • Papillion Research Center / Avacare

    Papillion, Nebraska · Recruiting

  • Dent Neurosciences Research Center, Inc

    Amherst, New York · Not yet recruiting

  • Upstate Clinical Research Associates, LLC

    Williamsville, New York · Recruiting

  • Hightower Clinical

    Oklahoma City, Oklahoma · Recruiting

  • Clinical Neuroscience Solutions, LLC.

    Memphis, Tennessee · Recruiting

  • FutureSearch Trials of Neurology

    Austin, Texas · Recruiting

  • Austin Clinical Trial Partners

    Austin, Texas · Recruiting

  • FutureSearch Trials of Dallas

    Dallas, Texas · Recruiting

  • Highland Clinical Research

    Salt Lake City, Utah · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Shaanxi Provincial People's Hospital

    Xi'an, Shaanxi, China · Not yet recruiting

  • Xianyang Hospital of Yan'an University

    Xianyang, Shaanxi, China · Not yet recruiting

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Not yet recruiting

  • Hillel Yaffe Medical Center

    Hadera, Israel · Recruiting

  • Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • Rabin Medical Center

    Petah Tikva, Central District, Israel · Not yet recruiting

  • Sheba Medical Center

    Ramat Gan, Central District, Israel · Not yet recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Jerusalem, Israel · Recruiting

  • St Pancras Clinical Research - London

    London, United Kingdom · Recruiting

  • Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Re:Cognition Health - London

    London, United Kingdom · Not yet recruiting

  • University Hospitals Sussex NHS Foundation Trust

    Brighton, EAST Sussex, United Kingdom · Not yet recruiting

  • Hull University Teaching Hospitals NHS Trust

    Hull, EAST Yorkshire, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.